Akeso, Inc. Promotes the Deployment of Innovative Pipeline Global Cooperation Appoints Dr. Michael (Chen) Chen as Business Development Vice President
2020-07-30
Akesobio Announced NMPA Accepts its new drug Penpulimab (PD-1 Monoclonal Antibody) for the Treatment of relapsed or refractory Classic Hodgkin's Lymphoma
2020-05-25
Akesobio Doses First Patient in Phase 1 Study of AK117， a novel anti-CD47 monoclonal antibody in Australia
2020-05-11
AACR 2020 | Akesobio presents phase Ib/II preliminary results of AK104, a PD-1/CTLA-4 bispecific antibody in combination with chemotherapy as first-line therapy in patients (pts) with advanced gastric (G) or gastroesophageal junction (GEJ) cancer
2020-04-02